Kirsten completed her MChem degree in chemistry with medicinal chemistry at the University of St Andrews. As part of this, she spent a year at Novartis in Basel working on an inhibitor program. Subsequently, she joined the group of Prof. J. Stephen Clark at the University of Glasgow where she completed her PhD in the total synthesis of furanocembrane natural products. She then made the move to Cambridge and joined AstraZeneca as a postdoctoral research fellow, focussing on the optimisation of covalent inhibitors. Kirsten then joined the drug discovery unit at the Beatson Institute (now CRH) where she worked as a medicinal chemist and fragment lead. She took on the role of ACBI Team Leader in November 2022 and in her spare time enjoys travelling and going to the gym.